Table 1.
Baseline characterstics.
| Variable | Frequency n = 104 (%) |
|---|---|
| Median age (range) in years | 31 (22–42) |
| Antepartum Cohort (BCP) | 34 (32.7) |
| Postpartum cohort (BCPP) | 70 (67.3) |
| Multiparous | 93 (92%) |
| Family history of cancer | 25 (24) |
| Median duration of symptoms [IQR] | 6 [3−12] |
| Delayed diagnosis | 77(74%) |
| Laterality | |
| Right | 53 (51) |
| Left | 51 (49) |
| Trimester | |
| 1–12weeks | 36 (61) |
| >12 to <24 | 16 (27.1) |
| >24 to <36 | 7 (11) |
| Missing | 45 |
| ECOG PS | |
| 0 | 59 (56.7) |
| 1 | 41 (39.4) |
| ≥2 | 4 (3.9) |
| Median BMI [IQR] | 24 [21–28] |
| Disease Characteristics | |
| TNBC | 43 (41.3) |
| Her2 positive and HR negative | 14 (13.5) |
| Her2 and HR positive (Triple positive) | 16 (15.4) |
| Her2 negative and HR positive | 31 (29.8) |
| Stagea | |
| EBC | 24 (23.1) |
| LABC | 51 (49) |
| MBC | 29 (27.9) |
| Grade(IDC GradeIII) | 101(97%) |
| Median week of pregnancy [IQR] | 14 [6.15–24] |
|
Treatment Characteristics | |
|
Systemic Therapy |
|
| Taxanes + Anthracyclines | 69 |
| Anthracyclines alone | 12 |
| Taxanes Alone | 10 |
| Taxanes + Carboplatin | 4 |
| Hormonal Therapy Alone | 4 |
| Trastuzumab received (n = 21 out of 30 eligible) | 15(EBC &LABC): 12 weeks (n = 9); 1year (n = 6) 6 (MBC): palliative intent trastuzumab |
| Surgery (n=65; 68 breast surgeries) | |
| Mastectomy | 27 |
| Breast Conserving Surgery | 39 |
| Breast Reconstruction | 2 |
| Locoregional Radiation Received | 77 (74) |
IQR= Interquartile Range; ECOG: Eastern Cooperative Oncology Group; PS: Performance Status.
BMI: Body Mass Index; HR= Hormone Receptors; EBC = Early Breast Cancer; LABC = Locally Advanced Breast Cancer; MBC = Metastatic Breast Cancer.
a
Stage is defined as per the standard AJCCC staging system eighth edition [37].